AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3556892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 59
Study 3556892 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 59
Study 3556892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 30240907 — intervention group
Group type: EXPERIMENTAL
Intervention: Different radioactive tracers and unilateral ligation of cervical lymph vessels
Number of subjects: 0
Study 30240907 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy (SEM) examination of lymphatic vessels
Number of subjects: 0
Study 30240907 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial dye lymphography
Number of subjects: 0
Study 30240907 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast injection in conjunctival lymphatics
Number of subjects: 0
Study 29202568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid hyaluronic acid (two intrarticular injections)
Number of subjects: 48
Study 29202568 — intervention group
Group type: COMPARATOR
Intervention: High molecular weight hyaluronic acid (two intrarticular injections)
Number of subjects: 48
Study 26518870 — intervention group
Group type: EXPERIMENTAL
Intervention: HOCO-DHA (50 g/day) in muffins and cookies
Number of subjects: 35
Study 26518870 — intervention group
Group type: COMPARATOR
Intervention: Barley flour (4.36 g/day of β-glucan) and control oil (50 g/day)
Number of subjects: 35
Study 26518870 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/day; DHA dosage 3 g/day)
Number of subjects: 35
Study 26518870 — intervention group
Group type: COMPARATOR
Intervention: All-purpose flour and control oil (50 g/day)
Number of subjects: 35
Study 23544862 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal umbilical artery Doppler velocimetry
Number of subjects: 54
Study 23544862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal FVL carriership
Number of subjects: 54
Study 21422865 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling surgery
Number of subjects: 0
Study 19748675 — intervention group
Group type: EXPERIMENTAL
Intervention: VPDT + ITA (4 mg ITA injection)
Number of subjects: 100
Study 19748675 — intervention group
Group type: COMPARATOR
Intervention: VPDT alone (sham injection)
Number of subjects: 100
Study 17761080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting trocars (single or pyramidal bladed)
Number of subjects: 56
Study 17761080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilating trocars (radially or axially dilating)
Number of subjects: 56
Study 17761080 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially dilating trocar
Number of subjects: 56
Study 17761080 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 disposable trocars (muscle cutting or dilating type)
Number of subjects: 56
Study 15139789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron 0.25 mg
Number of subjects: 1799
Study 15139789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron 0.75 mg
Number of subjects: 1799
Study 15139789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron (0.25 or 0.75 mg)
Number of subjects: 1799
Study 15139789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron 32 mg
Number of subjects: 1799
Study 15139789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dolasetron 100 mg
Number of subjects: 1799
Study 15139789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dolasetron
Number of subjects: 1799
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 13-cis-retinoic acid
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II HNSCC
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I HNSCC
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cavity site
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II disease
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I disease
Number of subjects: 1191
Study 11489748 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking-related SPT development rates
Number of subjects: 1191
Study 10204713 — intervention group
Group type: EXPERIMENTAL
Intervention: First degree relatives of M/TMD probands
Number of subjects: 224
Study 10204713 — intervention group
Group type: COMPARATOR
Intervention: First degree relatives of controls
Number of subjects: 224
Study 7719394 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise program
Number of subjects: 43
Study 7719394 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 43
Study 2292283 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 1.2 g single dose
Number of subjects: 25
Study 2292283 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 50 mg t.d.s. for three days
Number of subjects: 25
Study 372266 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 80
Study 372266 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction group
Number of subjects: 80
Study 372266 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 372266 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control group
Number of subjects: 80
Study 31550958 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound glycyrrhizin combined with fractional CO2 laser and triamcinolone acetonide solution
Number of subjects: 0
Study 31550958 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser and triamcinolone acetonide solution (Control)
Number of subjects: 0
Study 31550958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (including Control)
Number of subjects: 0
Study 28847206 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg once daily
Number of subjects: 30449
Study 28847206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30449
Study 28847206 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 30449
Study 28847206 — intervention group
Group type: COMPARATOR
Intervention: Anacetrapib and Placebo
Number of subjects: 30449
Study 24763358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) for 8 weeks
Number of subjects: 77
Study 24763358 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 77
Study 23265982 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of capsaicin
Number of subjects: 17
Study 23265982 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of menthol
Number of subjects: 17
Study 21332817 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg per os daily (n = 33)
Number of subjects: 66
Study 21332817 — intervention group
Group type: COMPARATOR
Intervention: TURP (n = 33)
Number of subjects: 66
Study 19874160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline social support
Number of subjects: 0
Study 19874160 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment social support
Number of subjects: 0
Study 16696911 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XFZYD)
Number of subjects: 50
Study 16696911 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular therapy)
Number of subjects: 50
Study 14566102 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of prednisolone
Number of subjects: 29
Study 14566102 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of prednisolone
Number of subjects: 29
Study 14566102 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 10660503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1 g
Number of subjects: 42
Study 10660503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2 g
Number of subjects: 42
Study 9031407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 55
Study 1500478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 70
Study 1500478 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 70
Study 6142467 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg zopiclone
Number of subjects: 40
Study 6142467 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 40
Study 2433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) given perioperatively and 3 and 6 months postoperatively at a dosage of 150 mg per course (total: 450 mg)
Number of subjects: 74
Study 2433653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 74
Study 2433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage I
Number of subjects: 74
Study 2433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage II
Number of subjects: 74
Study 2433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) for stage III
Number of subjects: 74
Study 28840401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural adolescents
Number of subjects: 6316
Study 28840401 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban adolescents
Number of subjects: 6316
Study 28840401 — intervention group
Group type: COMPARATOR
Intervention: Urban participants
Number of subjects: 6316
Study 28840401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural participants
Number of subjects: 6316
Study 26860055 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (VRT)
Number of subjects: 24
Study 26860055 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 24
Study 24754065 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled exercise training (ET) for 6 weeks in Group S
Number of subjects: 100
Study 24754065 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise training (ET+) in Subgroup A (51 patients)
Number of subjects: 100
Study 24754065 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise training (ET-) in Subgroup B (46 patients)
Number of subjects: 100
Study 24754065 — intervention group
Group type: COMPARATOR
Intervention: Patients in Group C who trained at home
Number of subjects: 100
Study 24754065 — intervention group
Group type: COMPARATOR
Intervention: Patients in Group C who refused home ET
Number of subjects: 100
Study 22851298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified care and service during waiting time (100 minutes average waiting time)
Number of subjects: 100
Study 22851298 — intervention group
Group type: COMPARATOR
Intervention: Regular care (81 minutes average waiting time)
Number of subjects: 100
Study 20467011 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g twice daily) with hypocaloric diet
Number of subjects: 16
Study 20467011 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 16
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 0
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 250 mg twice daily
Number of subjects: 0
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 0
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg once daily
Number of subjects: 0
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 0
Study 18192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0
Study 15914991 — intervention group
Group type: EXPERIMENTAL
Intervention: APF application followed by rinsing with water immediately after
Number of subjects: 0
Study 15914991 — intervention group
Group type: COMPARATOR
Intervention: APF application followed by no rinsing or consuming of liquids or solids for 30 min
Number of subjects: 0
Study 15914991 — intervention group
Group type: EXPERIMENTAL
Intervention: APF application followed by washing with water jet
Number of subjects: 0
Study 15914991 — intervention group
Group type: EXPERIMENTAL
Intervention: APF application followed by drinking a glass of water
Number of subjects: 0
Study 12839527 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese version of the Social Adjustment Scale-Self Report (SAS-SR)
Number of subjects: 1944
Study 10788200 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy labelled drink
Number of subjects: 0
Study 10788200 — intervention group
Group type: COMPARATOR
Intervention: Control information drink
Number of subjects: 0
Study 9065105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma‐globulin 1 gm/kg per week
Number of subjects: 54
Study 9065105 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gamma‐globulin 1 gm/kg per week with dexamethasone
Number of subjects: 54
Study 9065105 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment with 60 mg of prednisone per day
Number of subjects: 54
Study 1326165 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment with myelopid (MP)
Number of subjects: 40
Study 1326165 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with myelopid (MP)
Number of subjects: 40
Study 1326165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1326165 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelopid (MP) in patients with immunologic signs of pathological process activation
Number of subjects: 40
Study 6418094 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) + Nifedipine (30 mg/day)
Number of subjects: 10
Study 6418094 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg/day) + Placebo (3 tablets/day)
Number of subjects: 10
Study 6418094 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg/day) + Placebo (3 tablets/day) during Phase II
Number of subjects: 10
Study 30188363 — intervention group
Group type: EXPERIMENTAL
Intervention: BFRRE (Blood Flow-Restricted Resistance Exercise)
Number of subjects: 17
Study 30188363 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (Con)
Number of subjects: 17
Study 29061084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with resistance adjusted to 30% of maximal inspiratory pressure, 90 breaths a day, 5 times a week for 6 weeks
Number of subjects: 30
Study 29061084 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 30
Study 29061084 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular physical therapy)
Number of subjects: 30
Study 26577065 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg oral pure THCV administered daily for five days
Number of subjects: 10
Study 26577065 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg intravenous THC administered on the fifth day
Number of subjects: 10
Study 26577065 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for five days
Number of subjects: 10
Study 26577065 — intervention group
Group type: EXPERIMENTAL
Intervention: THC under THCV condition
Number of subjects: 10
Study 26577065 — intervention group
Group type: EXPERIMENTAL
Intervention: THCV in combination with THC
Number of subjects: 10
Study 24438504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with sorafenib (800 mg daily) and transcatheter arterial infusion (TAI) with cisplatin (65 mg/m2/cycle)
Number of subjects: 20
Study 20443800 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient liner attachment
Number of subjects: 30
Study 20443800 — intervention group
Group type: COMPARATOR
Intervention: Clip attachment
Number of subjects: 30
Study 18678161 — intervention group
Group type: EXPERIMENTAL
Intervention: Shu-needling therapy
Number of subjects: 102
Study 18678161 — intervention group
Group type: COMPARATOR
Intervention: Routine needling method
Number of subjects: 102
Study 15951542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine enema (1 g at bedtime)
Number of subjects: 127
Study 15951542 — intervention group
Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 127
Study 12700159 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous feeding with a mixed nutrient drink for 10 hours
Number of subjects: 12
Study 12700159 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 22 hours
Number of subjects: 12
Study 11035610 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA PCR
Number of subjects: 395
Study 11035610 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA PCR
Number of subjects: 395
Study 11035610 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load of RNA-positive specimens
Number of subjects: 395
Study 8852905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 60
Study 8852905 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV)
Number of subjects: 60
Study 1642935 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac 2 mg kg‐1/24 h for 2 days
Number of subjects: 30
Study 6377959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled‐release morphine (MST 30 mg)
Number of subjects: 50
Study 6377959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30771622 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention on speech stream
Number of subjects: 0
Study 30771622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverted attention from speech stream
Number of subjects: 0
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training course
Number of subjects: 18
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert physicians
Number of subjects: 18
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS global performance score
Number of subjects: 18
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS checklist score
Number of subjects: 18
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM checklist score
Number of subjects: 18
Study 29346221 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM global performance score
Number of subjects: 18
Study 28134943 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (n = 32)
Number of subjects: 64
Study 28134943 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative recovery (n = 32)
Number of subjects: 64
Study 24533522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-set (CS) protocol
Number of subjects: 11
Study 24533522 — intervention group
Group type: COMPARATOR
Intervention: Traditional set (TS) protocol
Number of subjects: 11
Study 22243564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleurone-rich cereal products (27 g aleurone/d)
Number of subjects: 79
Study 22243564 — intervention group
Group type: COMPARATOR
Intervention: Control products balanced for fibre and macronutrients
Number of subjects: 79
Study 20371148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports Climbing (SC)
Number of subjects: 20
Study 20371148 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 20
Study 20371148 — intervention group
Group type: COMPARATOR
Intervention: Control (Yoga)
Number of subjects: 20
Study 20371148 — intervention group
Group type: COMPARATOR
Intervention: Control (Sports Climbing)
Number of subjects: 20
Study 18581941 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (ALB, 16 mg x d(-1))
Number of subjects: 36
Study 18581941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, lactose)
Number of subjects: 36
Study 18581941 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (ALB)
Number of subjects: 36
Study 18581941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study 15754176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror (viewing a mirror‐reflection of the active hand)
Number of subjects: 8
Study 15754176 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (viewing the active hand)
Number of subjects: 8
Study 15754176 — intervention group
Group type: COMPARATOR
Intervention: Central (viewing a mark positioned between hands)
Number of subjects: 8
Study 15754176 — intervention group
Group type: COMPARATOR
Intervention: Inactive (viewing the inactive hand)
Number of subjects: 8
Study 15754176 — intervention group
Group type: COMPARATOR
Intervention: Rest (both hands at rest)
Number of subjects: 8
Study 12685519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 10204564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaver model training
Number of subjects: 23
Study 10204564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench model training
Number of subjects: 23
Study 10204564 — intervention group
Group type: COMPARATOR
Intervention: Text learning
Number of subjects: 23
Study 7604951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms once daily
Number of subjects: 0
Study 7604951 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice daily
Number of subjects: 0
Study 7604951 — intervention group
Group type: COMPARATOR
Intervention: Oral terfenadine 60 mg twice daily
Number of subjects: 0
Study 7604951 — intervention group
Group type: COMPARATOR
Intervention: Oral astemizole 10 mg once daily
Number of subjects: 0
Study 2113796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg orally
Number of subjects: 200
Study 2113796 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 200
Study 360846 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.1%, 0.25%, and 0.5%)
Number of subjects: 36